Table 2.

Comparison of parallel tumour and germline testing results from this study with similar recent studies

	This study	Koczkowska, 2016 15	Eoh, 2020 16	Peixoto, 2020 17
Number of patients	169	97	98	95
Setting	AWMGS, Wales	Medical University of Gdansk, Poland	Severance Hospital, South Korea	Portuguese Oncology Institute of Porto, Portugal
Testing criteria	High‐grade serous ovarian/fallopian tube/peritoneal cancer	Serous ovarian carcinoma	High‐grade serous ovarian cancer	High‐grade serous ovarian cancer
Overall (somatic and/or germline) pathogenic variant detection rate	25 (14.8%)	27 (27.8%)	24 (24.5%)	22 (23.2%)
Acquired pathogenic variant rate	11 (6.5%)	4 (4.1%)	7 (7.1%)	6 (6.3%)

Data presented as number of patients (%).